Skip to main content

Table 1 Initial characteristics and outcome of the prone positioned ARDS COVID-19 population (data are expressed as median (interquartile range, IQR) or number (%) as appropriate. After visual assumption of normality, Wilcoxon rank tests were applied for continuous variables. For categorical variables, Fisher’s exact or chi2 tests were applied as appropriate)

From: Usefulness and safety of a dedicated team to prone patients with severe ARDS due to COVID-19

Variables n, total available Total, n(%) or median (IQR) (n = 63) n, available for ICU survivors (n = 46) * ICU survivors, n(%) or median (IQR) * n, available for ICU non-survivors (n = 16)* ICU non-survivors, n(%) or median (IQR) * p
Demographic data
 Female ratio 63 15 (24%) 46 10 (22%) 16 5 (31%) 0.50
 Age (years) 63 64 (56–70) 46 62 (54–69) 16 67 (64–74) 0.045
 Weight (kg) 61 89 (75–103) 45 90 (80–103) 15 89 (73–106) 0.68
 Body mass index (kg/m2) 61 30 (25–36) 45 30 (26–35) 15 29 (25–46) 0.87
 SAPS II 63 42 (31–57) 46 37 (27–57) 16 46 (42–59) 0.030
Medical history
 Diabetes mellitus 63 17 (27%) 46 11 (24%) 16 5 (31%) 0.74
 Hypertension 63 30 (48%) 46 19 (41%) 16 10 (62%) 0.14
 Chronic respiratory disease 63 16 (25%) 46 13 (28%) 16 3 (19%) 0.53
 Chronic immunosuppression† 63 5 (8%) 46 2 (4%) 16 3 (19%) 0.10
 Chronic Cardiovascular disease 63 16 (25%) 46 12 (26%) 16 3 (19%) 0.74
 Chronic kidney disease 63 3 (5%) 46 2 (4%) 16 1 (6%) 1.00
Respiratory parameters
 Static compliance (ml/cmH2O) before first prone positioning 46 33 (23–42) 35 35 (27–44) 11 22 (18–36) 0.036
 PaO2/FIO2 ratio before first prone positioning 63 92 (70–117) 46 96 (70–120) 16 86 (64–111) 0.54
 Number of prone positioning per patient 63 3 (2–6) 46 3 (2–6) 16 4 (3–8) 0.19
Events in ICU
 Vasopressors administered 63 38 (60%) 46 23 (50%) 16 14 (88%) 0.008
 VV-ECMO 63 14 (22%) 46 11 (24%) 16 3 (19%) 1.00
 Renal replacement therapy 63 8 (13%) 46 4 (9%) 16 4 (25%) 0.19
 ICU length of stay (days) 62 19 (14–31) 46 20 (15–32) 16 16 (12–28) 0.24
  1. *1 patient still in ICU
  2. Representing active cancer medical history or chronic immunosuppressor therapies